<DOC>
	<DOCNO>NCT01250145</DOCNO>
	<brief_summary>This study Phase 1 , multi-center , 2-part , subject- investigator-blind , randomize , placebo-controlled , multiple dose study transdermal teriparatide ( 80-Âµg dose ) healthy postmenopausal woman . Part A examine cumulative irritation adherence transdermal patch , Part B examine skin sensitization adherence . Two separate group subject enrol Part A Part B study . All screening procedure take place 28 day prior enrollment .</brief_summary>
	<brief_title>A Multiple-Dose Study Evaluate Skin Irritation Sensitization Teriparatide Administered Transdermally Healthy Postmenopausal Women</brief_title>
	<detailed_description />
	<mesh_term>Osteoporosis</mesh_term>
	<mesh_term>Osteoporosis , Postmenopausal</mesh_term>
	<mesh_term>Teriparatide</mesh_term>
	<criteria>Are overtly healthy postmenopausal female , determine medical history , physical examination , vital sign , electrocardiogram ( ECG ) , laboratory test ( example , subject osteoporosis stable and/or control hyperlipidemia , hypertension , and/or hypothyroidism may enter investigator judge appropriate participation study ) . Postmenopausal woman include woman least 6weeks postsurgical bilateral oophorectomy without hysterectomy , confirm medical history , spontaneous amenorrhea least 6 12 month , induce medical condition anorexia nervosa take medication amenorrhea induce amenorrhea ( eg , oral contraceptive , hormone , gonadotropinreleasing hormone , antiestrogens , selective estrogen receptor modulators , chemotherapy ) folliclestimulating hormone level great 40 mIU/mL . Have clinical laboratory test result within normal reference range population investigator site , result acceptable deviation judge clinically significant investigator . Have sit blood pressure pulse rate judge clinically significant investigator . Are reliable willing make available duration study willing follow study procedure . Have give write informed consent approve Eli Lilly Company ( Lilly ) ethical review board ( ERB ) govern site . Are currently enrol , discontinue within last 3 month , clinical trial involve investigational drug device offlabel use drug device , concurrently enrol type medical research judge scientifically medically compatible study . Have know hypersensitivity teriparatide excipients . Are person previously complete withdrawn study study investigate teriparatide patch . Have abnormality 12lead ECG , opinion investigator , increase risk associate participate study . Have history presence cardiovascular , respiratory , hepatic , renal , gastrointestinal , endocrine , hematological , neurological disorder capable significantly alter absorption , metabolism , elimination drug ; constitute risk take study medication ; interfere interpretation data . Regularly use know drug abuse and/or show positive finding urinary drug screening . Show evidence human immunodeficiency virus ( HIV ) and/or positive human HIV antibody . Show evidence hepatitis C and/or positive hepatitis C antibody . Show evidence hepatitis B and/or positive hepatitis B surface antigen . Have history breast cancer within past 10 year type carcinoma within past 5 year , except excise superficial skin tumor adequately treat situ carcinoma cervix . Have average weekly alcohol intake exceed 14 unit per week , ( 1 unit = 12 oz 360 mL beer ; 5 oz 150 mL wine ; 1.5 oz 45 mL distilled spirit ) . Have hyperparathyroidism hypoparathyroidism . Have hyperthyroidism . Have hypercalciuria ( 24hour collection 300 mg/day ) . Have hypercalcemia ( upper limit reference range ) . Have history bone diseases Paget 's disease bone , bone carcinoma , bone metastasis , metabolic bone disease osteoporosis , unexplained elevation serum alkaline phosphatase level . Have history external beam implant radiation involve skeleton . Have history recurrent nephrolithiasis , single episode within past 5 year . Eligible subject episode within past 5 10 year must kidneyureterbladder Xray abdominal area within 1 month prior enrollment study , indicate exist stone . Have history bleeding disorder within past 3 year . Are currently use therapy osteoporosis ; use hormone replacement therapy bisphosphonates previous 3 month . Women receive shortterm hormone therapy treatment moderate severe menopausal symptom may enrol postmenopausal status confirm inclusion criterion . Have presence dermatologic disease might interfere evaluation test site reaction ; clinically significant scar , wound , discoloration , abnormality skin near intend site electrode application ( example , porphyria , atopy , psoriasis , vitiligo ) . Have history severe skin infection within past year opinion investigator . Have history skin allergy hypersensitivity tap adhesive , opinion investigator . Have history significant dermatologic cancer ( example , melanoma , squamous cell carcinoma ) , except basalcell carcinomas superficial involve investigative site . Have obvious difference skin color arm presence skin condition , excessive hair application site , scar tissue , tattoo , coloration would interfere placement test article , skin assessment , reaction drug . Have implant externally mounted electrical electronic medical device ( example , pacemaker ) . Have use topical analgesic topical corticosteroid within 3 week study enrollment . Have take antihistamine within 72 hour prior dose . Any condition , opinion investigator , would preclude participation study .</criteria>
	<gender>Female</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2012</verification_date>
</DOC>